Education
About Us
Working with TipRanks
Follow Us
Sonoma Pharmaceuticals (SNOA)
NASDAQ:SNOA
SNOA Stock Chart & Stats
$3.55
-$0.06(-2.19%)
At close: 4:00 PM EST
$3.55
-$0.06(-2.19%)
Day’s Range― - ―
52-Week Range$1.75 - $6.92
Previous CloseN/A
Volume16.09K
Average Volume (3M)65.28K
Market Cap
$5.75M
Enterprise Value$1.74M
Total Cash (Recent Filing)$3.04M
Total Debt (Recent Filing)$535.00K
Price to Earnings (P/E)―
Beta1.99
Next Earnings
Feb 17, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding1,701,076
10 Day Avg. Volume126,678
30 Day Avg. Volume65,281
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.62
Price to Sales (P/S)0.19
P/FCF Ratio-16.18
Enterprise Value/Market Cap0.30
Enterprise Value/Revenue0.10
Enterprise Value/Gross Profit0.27
Enterprise Value/Ebitda-0.51
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Sonoma Pharmaceuticals News
SNOA FAQ
What was Sonoma Pharmaceuticals’s price range in the past 12 months?
Sonoma Pharmaceuticals lowest stock price was $1.75 and its highest was $6.92 in the past 12 months.
What is Sonoma Pharmaceuticals’s market cap?
Sonoma Pharmaceuticals’s market cap is $5.75M.
When is Sonoma Pharmaceuticals’s upcoming earnings report date?
Sonoma Pharmaceuticals’s upcoming earnings report date is Feb 17, 2026 which is in 60 days.
How were Sonoma Pharmaceuticals’s earnings last quarter?
Sonoma Pharmaceuticals released its earnings results on Nov 04, 2025. The company reported -$0.129 earnings per share for the quarter, beating the consensus estimate of -$0.31 by $0.181.
Is Sonoma Pharmaceuticals overvalued?
According to Wall Street analysts Sonoma Pharmaceuticals’s price is currently Overvalued.
Does Sonoma Pharmaceuticals pay dividends?
Sonoma Pharmaceuticals does not currently pay dividends.
What is Sonoma Pharmaceuticals’s EPS estimate?
Sonoma Pharmaceuticals’s EPS estimate is -0.29.
How many shares outstanding does Sonoma Pharmaceuticals have?
Sonoma Pharmaceuticals has 1,701,076 shares outstanding.
What happened to Sonoma Pharmaceuticals’s price movement after its last earnings report?
Sonoma Pharmaceuticals reported an EPS of -$0.129 in its last earnings report, beating expectations of -$0.31. Following the earnings report the stock price went down -0.529%.
Which hedge fund is a major shareholder of Sonoma Pharmaceuticals?
Currently, no hedge funds are holding shares in SNOA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sonoma Pharmaceuticals
Sonoma Pharmaceuticals, Inc. (SNOA) is a biotechnology company focused on developing and commercializing innovative therapeutic products for the treatment of dermatological, ophthalmic, and wound care conditions. The company leverages its proprietary technology platform to create and manufacture safe and effective solutions based on its patented formulation of hypochlorous acid, which is utilized in various products targeting infection, inflammation, and tissue healing across multiple healthcare sectors.
Technical Analysis
China Pharma Holdings
―
Evoke Pharma
―
RedHill Biopharma
―
Sunshine Biopharma
―
Shuttle Pharmaceuticals Holdings, Inc.
―
Ownership Overview
29.86%
Insiders
1.20% Mutual Funds
1.00% Other Institutional Investors
66.83% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---